Logo image of PASW

PING AN BIOMEDICAL CO LTD (PASW) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PASW - KYG5880S1057 - Common Stock

0.4568 USD
-0.02 (-3.59%)
Last: 11/28/2025, 7:54:08 PM
0.452 USD
0 (-1.05%)
After Hours: 11/28/2025, 7:54:08 PM
Fundamental Rating

1

Taking everything into account, PASW scores 1 out of 10 in our fundamental rating. PASW was compared to 23 industry peers in the Distributors industry. PASW may be in some trouble as it scores bad on both profitability and health. PASW is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PASW had negative earnings in the past year.
PASW had a positive operating cash flow in the past year.
PASW Yearly Net Income VS EBIT VS OCF VS FCFPASW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 5M -5M 10M 15M 20M

1.2 Ratios

The Return On Assets of PASW (-11.35%) is worse than 69.57% of its industry peers.
Industry RankSector Rank
ROA -11.35%
ROE N/A
ROIC N/A
ROA(3y)1.77%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PASW Yearly ROA, ROE, ROICPASW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 50 100 150

1.3 Margins

Looking at the Gross Margin, with a value of 4.46%, PASW is doing worse than 78.26% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for PASW so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 4.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PASW Yearly Profit, Operating, Gross MarginsPASW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 2 4 6 8 10

More info and screens

3

2. Health

2.1 Basic Checks

PASW does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PASW has about the same amount of shares outstanding.
The debt/assets ratio for PASW has been reduced compared to a year ago.
PASW Yearly Shares OutstandingPASW Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M
PASW Yearly Total Debt VS Total AssetsPASW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 1.93 indicates that PASW is not a great score, but indicates only limited risk for bankruptcy at the moment.
PASW has a Altman-Z score of 1.93. This is in the lower half of the industry: PASW underperforms 65.22% of its industry peers.
The Debt to FCF ratio of PASW is 0.91, which is an excellent value as it means it would take PASW, only 0.91 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of PASW (0.91) is better than 82.61% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0.91
Altman-Z 1.93
ROIC/WACCN/A
WACC5.67%
PASW Yearly LT Debt VS Equity VS FCFPASW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

A Current Ratio of 0.77 indicates that PASW may have some problems paying its short term obligations.
PASW has a worse Current ratio (0.77) than 82.61% of its industry peers.
PASW has a Quick Ratio of 0.77. This is a bad value and indicates that PASW is not financially healthy enough and could expect problems in meeting its short term obligations.
PASW has a Quick ratio (0.76) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.76
PASW Yearly Current Assets VS Current LiabilitesPASW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

PASW shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -707.05%.
The Revenue for PASW has decreased by -17.49% in the past year. This is quite bad
EPS 1Y (TTM)-707.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2127.59%
Revenue 1Y (TTM)-17.49%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-60.13%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PASW Yearly Revenue VS EstimatesPASW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PASW. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PASW Price Earnings VS Forward Price EarningsPASW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, PASW is valued cheaper than 82.61% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.01
EV/EBITDA N/A
PASW Per share dataPASW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PASW does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PING AN BIOMEDICAL CO LTD

NASDAQ:PASW (11/28/2025, 7:54:08 PM)

After market: 0.452 0 (-1.05%)

0.4568

-0.02 (-3.59%)

Chartmill FA Rating
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustryDistributors
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.03%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.36M
Revenue(TTM)105.85M
Net Income(TTM)-5.52M
AnalystsN/A
Price TargetN/A
Short Float %0.6%
Short Ratio0.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.63
P/FCF 6.01
P/OCF 6.01
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.08
FCFY16.64%
OCF(TTM)0.08
OCFY16.64%
SpS0.73
BVpS-0.08
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.35%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 4.46%
FCFM 10.43%
ROA(3y)1.77%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover2.18
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0.91
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.76
Altman-Z 1.93
F-Score4
WACC5.67%
ROIC/WACCN/A
Cap/Depr(3y)33.6%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.01%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-707.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2127.59%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.49%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-60.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-311.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y340.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y340.52%
OCF growth 3YN/A
OCF growth 5YN/A

PING AN BIOMEDICAL CO LTD / PASW FAQ

Can you provide the ChartMill fundamental rating for PING AN BIOMEDICAL CO LTD?

ChartMill assigns a fundamental rating of 1 / 10 to PASW.


What is the valuation status of PING AN BIOMEDICAL CO LTD (PASW) stock?

ChartMill assigns a valuation rating of 2 / 10 to PING AN BIOMEDICAL CO LTD (PASW). This can be considered as Overvalued.


What is the profitability of PASW stock?

PING AN BIOMEDICAL CO LTD (PASW) has a profitability rating of 0 / 10.


What is the financial health of PING AN BIOMEDICAL CO LTD (PASW) stock?

The financial health rating of PING AN BIOMEDICAL CO LTD (PASW) is 3 / 10.